4PBA reduces growth deficiency in osteogenesis imperfecta by enhancing transition of hypertrophic chondrocytes to osteoblasts.
Author
Scheiber, Amanda LWilkinson, Kevin J
Suzuki, Akiko
Enomoto-Iwamoto, Motomi
Kaito, Takashi
Cheah, Kathryn Se
Iwamoto, Masahiro
Leikin, Sergey
Otsuru, Satoru
Date
2022-02-08Journal
JCI InsightPublisher
American Society for Clinical InvestigationType
Article
Metadata
Show full item recordAbstract
Short stature is a major skeletal phenotype in osteogenesis imperfecta (OI), a genetic disorder mainly caused by mutations in genes encoding type I collagen. However, the underlying mechanism is poorly understood, and no effective treatment is available. In OI mice that carry a G610C mutation in COL1A2, we previously found that mature hypertrophic chondrocytes (HCs) are exposed to cell stress due to accumulation of misfolded mutant type I procollagen in the endoplasmic reticulum (ER). By fate mapping analysis of HCs in G610C OI mice, we found that HCs stagnate in the growth plate, inhibiting translocation of HC descendants to the trabecular area and their differentiation to osteoblasts. Treatment with 4-phenylbutyric acid (4PBA), a chemical chaperone, restored HC ER structure and rescued this inhibition, resulting in enhanced longitudinal bone growth in G610C OI mice. Interestingly, the effects of 4PBA on ER dilation were limited in osteoblasts, and the bone fragility was not ameliorated. These results highlight the importance of targeting HCs to treat growth deficiency in OI. Our findings demonstrate that HC dysfunction induced by ER disruption plays a critical role in the pathogenesis of OI growth deficiency, which lays the foundation for developing new therapies for OI.Identifier to cite or link to this item
http://hdl.handle.net/10713/17947ae974a485f413a2113503eed53cd6c53
10.1172/jci.insight.149636
Scopus Count
Collections
Related articles
- Endoplasmic reticulum stress is induced in growth plate hypertrophic chondrocytes in G610C mouse model of osteogenesis imperfecta.
- Authors: Scheiber AL, Guess AJ, Kaito T, Abzug JM, Enomoto-Iwamoto M, Leikin S, Iwamoto M, Otsuru S
- Issue date: 2019 Jan 29
- Effect of rapamycin on bone mass and strength in the α2(I)-G610C mouse model of osteogenesis imperfecta.
- Authors: Bateman JF, Sampurno L, Maurizi A, Lamandé SR, Sims NA, Cheng TL, Schindeler A, Little DG
- Issue date: 2019 Mar
- The chaperone activity of 4PBA ameliorates the skeletal phenotype of Chihuahua, a zebrafish model for dominant osteogenesis imperfecta.
- Authors: Gioia R, Tonelli F, Ceppi I, Biggiogera M, Leikin S, Fisher S, Tenedini E, Yorgan TA, Schinke T, Tian K, Schwartz JM, Forte F, Wagener R, Villani S, Rossi A, Forlino A
- Issue date: 2017 Aug 1
- Osteoblast Malfunction Caused by Cell Stress Response to Procollagen Misfolding in α2(I)-G610C Mouse Model of Osteogenesis Imperfecta.
- Authors: Mirigian LS, Makareeva E, Mertz EL, Omari S, Roberts-Pilgrim AM, Oestreich AK, Phillips CL, Leikin S
- Issue date: 2016 Aug
- The effect of carbamazepine on bone structure and strength in control and osteogenesis imperfecta (Col1a2 (+/p.G610C) ) mice.
- Authors: Blank M, McGregor NE, Rowley L, Kung LHW, Crimeen-Irwin B, Poulton IJ, Walker EC, Gooi JH, Lamandé SR, Sims NA, Bateman JF
- Issue date: 2022 Jul